Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE: 600222)
Health Care · Pharmaceuticals · CN
CN¥7.84
-3.69% today · +14.1% 1Y
Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE: 600222) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $644.85M and employs 2,084 people.
Over the last twelve months the share price has gained 14.1%, trading between 6.13 and 9.44.
Tweenvest scores Henan Taloph Pharmaceutical Stock Co.,Ltd across four factors: quality 63/100, value 43/100, growth 29/100, dividend 7/100. Its strongest factor is quality.
600222 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $644.85M
- Revenue (TTM)
- $258.76M
- P/E
- 71.21
- EPS
- 0.11
- Dividend yield
- 0.18%
- Beta (5Y)
- 0.71
- 52-week high
- CN¥9.44
- 52-week low
- CN¥6.13
- Avg volume (3M)
- —
- Shares outstanding
- 552.92M
- Employees
- 2,084
- Next earnings
- —
About Henan Taloph Pharmaceutical Stock Co.,Ltd
Operating from Zhengzhou, China, Henan Taloph Pharmaceutical Stock Co., Ltd. specializes in the research, development, production, and sale of a wide array of Chinese and Western medicines across the nation. The company's product line encompasses various forms, such as oral liquids, tablets, capsules, and injectable fluids. Notable products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, and pazufloxacin mesylate sodium chloride injections, alongside a selection of other infusion products. Taloph Pharmaceutical serves a diverse client base, including hospitals, pharmacies, and direct consumers. It was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd.
- ISIN
- CNE0000010L8
- Founded
- 1998
- Listed since
- Nov 5, 1999
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.36 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.50 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.